BEAM
Medium convictionBeam Therapeutics Inc.
Healthcare · NASDAQ
$3.5B mkt cap
Brief updated Jun 19, 2026
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmenta
BEAM is a medium-conviction name in Healthcare
BEAM sits at the intersection of key themes currently active in the market. The scoring engine rates it medium based on how well the active market forces line up with its business, plus available fundamental data. Financial metrics and analyst consensus provide additional context.
Why now
The market forces active right now are aligned with the company's core business exposure. The timing reflects the intersection of theme strength and available catalyst data.
Key risks
Data availability limits full scoring across all dimensions. Market forces can reverse rapidly; theme exposure does not guarantee the price follows. Fundamental valuation data may not reflect the most recent quarterly results.
What to watch
Monitor conviction score changes, especially the macro and analyst dimensions. Earnings guidance updates and analyst consensus shifts are the primary near-term catalysts.
A Post-Iran War View on Energy Investing
The potential for a post-Iran war scenario is being considered in the context of energy investing, indicating a heightened state of geopolitical tension that could impact global energy markets and investments. This scenario suggests a significant risk to energy supply and prices.
Jun 5, 2026
Stocks Fall on Escalation of US-Iran Hostilities
The escalation of US-Iran hostilities has led to a decline in stock markets, as investors become increasingly risk-averse due to the potential for further conflict and its impact on global stability and oil prices.
Jun 5, 2026
Stocks Fall on Escalation of US-Iran Hostilities
The escalation of US-Iran hostilities has led to a decline in stock markets, as investors become increasingly risk-averse due to the potential for further conflict and its impact on global stability and oil prices.
Jun 5, 2026
US Equity Futures Mostly Lower Pre-Bell Amid Continued Tech Stock Sell-Off, US-Iran War Entering Fourth Month
The US-Iran war is entering its fourth month, and the continued conflict is contributing to a sell-off in tech stocks, which is affecting US equity futures. This prolonged conflict poses significant risks to global markets and stability.
Jun 5, 2026
Earnings surprises
-4.6%
2026-05
+91.2%
2026-02
-12.2%
2025-11
+3.9%
2025-08
-11.7%
2025-05
Generated Fri, 19 Jun 2026 05:00:46 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.